Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-09-21
2004-10-05
Richter, Johann (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S268100
Reexamination Certificate
active
06800647
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to the Form V polymorph of Compound A having the chemical structure shown below:
as well as a process for synthesizing the Form V polymorph.
Compound A exists in five polymorphic forms (Forms I-V), an amorphous form and two hydrated forms. The compound is a potent and selective cyclooxygenase-2 (COX-2) inhibitor, useful primarily in the treatment of inflammation, pain and fever as well as other COX-2 mediated diseases, such as described in PCT Publication Nos. WO96/10012 and WO96/16934. Compound A is described in U.S. Pat. No. 5,861,419 granted on Jan. 19, 1999 (Example 23), which is hereby incorporated by reference in its entirety. A process for making Compound A is described in U.S. Pat. No. 6,040,319 granted on Mar. 21, 2000, which is hereby incorporated by reference in its entirety. The present invention unexpectedly provides for a novel, robust process for making a Form V polymorph of compound A from any one of Forms I, II, III or IV or any mixture of polymorphs of compound A.
SUMMARY OF THE INVENTION
This invention encompasses the Form V polymorph of structural formula A:
which is useful in the treatment of cyclooxygenase-2 mediated diseases.
The invention encompasses certain pharmaceutical compositions for the treatment of cyclooxygenase-2 mediated diseases comprising the Form V polymorph of Compound A. The invention also encompasses a process for synthesizing the Form V polymorph of Compound A comprising: combining polymorph I, II, III or IV of Compound A with isopropyl acetate; heating to an elevated temperature less than about 75° C.; and cooling to a low temperature to produce the Form V polymorph.
REFERENCES:
patent: 5861419 (1999-01-01), Dube et al.
patent: 6040319 (2000-03-01), Corley et al.
patent: 6040450 (2000-03-01), Davies et al.
patent: 6127545 (2000-10-01), Pye et al.
patent: 6130334 (2000-10-01), Pye et al.
patent: 6204387 (2001-03-01), Davies et al.
patent: 6252116 (2001-06-01), Corley et al.
Friesen et. al., “2-pyridinyl -3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2-inhibitors”, Bioorganic & Medicinal Chemistry Letters 8 (1998) 2777-2782.*
“X-ray Techniques: Overview”, Ron Jenkins, Encyclopedia of Analytical Chemistry, R. A. Meyers (Ed.), pp. 13269-13288.*
Schumacher, Jr., et al., BMJ, pp. 1488-1492m vol. 324, 2002.
Mealy, et al., Drugs of the Future, pp. 403-434, 2002.
Roberts, Jackson, II, et al., Goodman & Gilman's Pharmalogical Basis ofTherapeutics, Chapter 27, pp. 687-731.
Crocker Loius S.
Davies Ian W.
Kotliar Andrew
Osifchin Richard G.
Merck & Co. , Inc.
Richter Johann
Robinson Binta M.
Rose David L.
Yuro Raynard
LandOfFree
5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3330981